Cargando…

Metabolomics-Based Discovery of Molecular Signatures for Triple Negative Breast Cancer in Asian Female Population

Triple negative breast cancer (TNBC) is a devastating cancer disease characterized by its poor prognosis, distinct metastatic patterns, and aggressive biological behavior. Research indicates that the prevalence and presentation of TNBC varies among races, with Asian TNBC patients more commonly prese...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Lixian, Zheng, Xiaodong, Zhou, Qi, Villanueva, Nathaniel, Nian, Weiqi, Liu, Xingming, Huan, Tao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962155/ https://www.ncbi.nlm.nih.gov/pubmed/31941951 http://dx.doi.org/10.1038/s41598-019-57068-5

Ejemplares similares

Metabolomics Reveals Molecular Signatures for Psoriasis Biomarkers and Drug Targets Discovery
por: Song, Qian, et al.
Publicado: (2023)

Immune-Related Gene Signatures to Predict the Effectiveness of Chemoimmunotherapy in Triple-Negative Breast Cancer Using Exploratory Subgroup Discovery
por: Kholod, Olha, et al.
Publicado: (2022)

Immunotherapeutic interventions of Triple Negative Breast Cancer
por: Li, Zehuan, et al.
Publicado: (2018)

A three-long noncoding RNA signature as a diagnostic biomarker for differentiating between triple-negative and non-triple-negative breast cancers
por: Liu, Man, et al.
Publicado: (2017)

Serum metabolomic signatures of gestational diabetes in South Asian and white European women
por: Sikorski, Claudia, et al.
Publicado: (2022)

MUC1 facilitates metabolomic reprogramming in triple-negative breast cancer
por: Goode, Gennifer, et al.
Publicado: (2017)

Comprehensive metabolomics expands precision medicine for triple-negative breast cancer
por: Xiao, Yi, et al.
Publicado: (2022)

Distinct microbiological signatures associated with triple negative breast cancer
por: Banerjee, Sagarika, et al.
Publicado: (2015)

An EMT-Related Gene Signature to Predict the Prognosis of Triple-Negative Breast Cancer
por: Zhang, Bo, et al.
Publicado: (2023)

Identification of immunosuppressive signature subtypes and prognostic risk signatures in triple-negative breast cancer
por: Ding, Ran, et al.
Publicado: (2023)

Ribosome Proteins Represented by RPL27A Mark the Development and Metastasis of Triple-Negative Breast Cancer in Mouse and Human
por: Zhao, Weipeng, et al.
Publicado: (2021)

A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women
por: Tseng, Ling-Ming, et al.
Publicado: (2017)

Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment
por: Masci, Domiziana, et al.
Publicado: (2023)

Identification of a Hypoxia-Related Molecular Classification and Hypoxic Tumor Microenvironment Signature for Predicting the Prognosis of Patients with Triple-Negative Breast Cancer
por: Sun, Xiaoli, et al.
Publicado: (2021)

Correction: MUC1 facilitates metabolomic reprogramming in triple-negative breast cancer
por: Goode, Gennifer, et al.
Publicado: (2017)

Metabolomic Impact of Lidocaine on a Triple Negative Breast Cancer Cell Line
por: Chamaraux-Tran, Thiên-Nga, et al.
Publicado: (2022)

Cytotoxic Lymphocyte-Related Gene Signature in Triple-Negative Breast Cancer
por: Han, Yiqun, et al.
Publicado: (2023)

On reliable discovery of molecular signatures
por: Nilsson, Roland, et al.
Publicado: (2009)

Microsatellite instability in Japanese female patients with triple-negative breast cancer
por: Kurata, Kanako, et al.
Publicado: (2020)

Identification of long non-coding RNA signatures in triple-negative breast cancer
por: Tian, Tian, et al.
Publicado: (2018)

Autophagy-related prognostic signature for survival prediction of triple negative breast cancer
por: Yang, Qiong, et al.
Publicado: (2022)

Stemness signature and targeted therapeutic drugs identification for Triple Negative Breast Cancer
por: Gul, Samina, et al.
Publicado: (2023)

Clinicopathological significance of Sox10 expression in triple-negative breast carcinoma
por: Jin, Linfang, et al.
Publicado: (2020)

Discovery and characterization of an immunogenic neoantigen in a patient with metastatic triple negative breast cancer
por: Assadipour, Yasmine, et al.
Publicado: (2015)

Discovery of HSPG2 (Perlecan) as a Therapeutic Target in Triple Negative Breast Cancer
por: Kalscheuer, Stephen, et al.
Publicado: (2019)

Prediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomics
por: Gámez-Pozo, Angelo, et al.
Publicado: (2017)

Integrating Germline and Somatic Mutation Information for the Discovery of Biomarkers in Triple-Negative Breast Cancer
por: Wu, Jiande, et al.
Publicado: (2019)

Drug Repositioning and Subgroup Discovery for Precision Medicine Implementation in Triple Negative Breast Cancer
por: Al-Taie, Zainab, et al.
Publicado: (2021)

Integrated multiomic data analysis reveals the clinical significance of TXNIP and contributing to immune microenvironment in triple negative breast cancer
por: Gong, Han, et al.
Publicado: (2023)

Distinct urine metabolome after Asian ginseng and American ginseng intervention based on GC-MS metabolomics approach
por: Yang, Liu, et al.
Publicado: (2016)

Epigenetic Profiles of Triple-Negative Breast Cancers of African American and White Females
por: Ensenyat-Mendez, Miquel, et al.
Publicado: (2023)

Molecular classification of triple-negative tumors
por: Prat, A, et al.
Publicado: (2011)

NMR-Based Metabolomics Analysis Predicts Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: He, Xiangming, et al.
Publicado: (2021)

AR negative triple negative or “quadruple negative” breast cancers in African American women have an enriched basal and immune signature
por: Davis, Melissa, et al.
Publicado: (2018)

Age-related mutational signature negatively associated with immune activity and survival outcome in triple-negative breast cancer
por: Chen, Hao, et al.
Publicado: (2020)

Gene expression profile analysis to discover molecular signatures for early diagnosis and therapies of triple-negative breast cancer
por: Alam, Md Shahin, et al.
Publicado: (2022)

A clinically relevant gene signature in triple negative and basal-like breast cancer
por: Rody, Achim, et al.
Publicado: (2011)

Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers
por: Klimov, Sergey, et al.
Publicado: (2017)

Three-microRNA expression signature predicts survival in triple-negative breast cancer
por: Wu, Xinquan, et al.
Publicado: (2020)

Mass Spectrometry-Based Omics for the Characterization of Triple-Negative Breast Cancer Bio-Signature
por: Pralea, Ioana-Ecaterina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f68ha13pbhce7g0kdqi2e4qcsj